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A recently developed polymerase chain reaction (PCR)-based cell culture neutralization assay was used to investigate
cross-neutralization of known hepatitis E virus (HEV) strains obtained from various HEV-endemic regions of the world with
different anti-HEV-positive serum samples. Serum specimens obtained from cynomolgus macaques experimentally infected
with strains from Burma, Mexico, or Pakistan cross-neutralized the infectivity of each strain as well as an isolate from
Morocco. Serum samples obtained either from infected patients who reside in HEV-endemic regions of the world or from U.S.
residents who became infected while traveling to such regions also neutralized all four strains. In contrast, antibodies
obtained from rabbits immunized with full-length Burma strain ORF2 protein neutralized only the Burma and Pakistan strains,
not the Mexico or Morocco strains. In addition, antibodies obtained from guinea pigs immunized with an N-terminal truncated
Burma strain ORF2 protein neutralized each strain except the Morocco strain. These data strongly suggest that antibodies
elicited during an HEV infection demonstrate broad HEV neutralizing activity, whereas antibodies elicited after immunization
with recombinant Burma ORF2 protein demonstrate a more limited ability to neutralize various HEV strains obtained from
different regions of the world endemic for the disease. © 1998 Academic Press
INTRODUCTION
The hepatitis E virus (HEV) causes acute viral hepatitis
worldwide; the highest incidence occurs within develop-
ing countries (Fields et al., 1993; Purcell, 1996). The
disease is transmitted mainly by the fecal-oral route,
often through contaminated water, and occurs in both
epidemic and sporadic forms (Balayan et al., 1983). HEV
infection appears to account for .50% of acute viral
hepatitis observed among young to middle-aged adults
(Datta et al., 1987) and is associated with an unusually
high mortality rate, up to 20%, in infected pregnant
women (Purcell and Ticehurst, 1988). Sporadic cases
have also been identified in developed countries, primar-
ily as a result of travelers who import the disease from
highly disease-endemic regions of the world (Centers for
Disease Control and Prevention, 1993). In regions of low
endemicity, such as the United States and Western Eu-
rope, the seroprevalence of antibodies to HEV (anti-HEV)
among normal blood donor populations has been deter-
mined to be 2–7% (Dawson et al., 1992).
HEV is an icosahedral, nonenveloped virus that is
27–34 nm in diameter with a single-strand, positive-
sense, polyadenylated RNA genome of ;7.5 kb in length
(Bradley et al., 1987; Reyes et al., 1990). The HEV genome
contains three open reading frames (ORF1, ORF2, and
ORF3). ORF1, which encodes for nonstructural proteins,
is the largest of the ORFs and is located within the
59-terminal part of the genome. ORF2, located within the
39-terminal part of the HEV genome, encodes capsid
protein. The smallest ORF, ORF3, overlaps ORF1 and
ORF2 and encodes an immunogenic protein of unknown
function (Tam et al., 1991).
The entire genome of several HEV strains from Asia
and North America (Mexico) has been sequenced (Tam
et al., 1991; Tsarev et al., 1992; Aye et al., 1992a, 1993;
Huang et al., 1992; Bi et al., 1993; Yin et al., 1994; Donati
et al., 1997). For some other strains, only partial se-
quences of the genome were identified (Aye et al., 1992b;
Yin et al., 1993; Huang et al., 1995; Panda et al., 1995;
Drabick et al., 1997; Gouvea et al., 1997). A comparison of
nucleotide sequences of different geographic HEV
strains revealed significant differences between the
Asian strains and the Mexican strain. The Asian strains,
although very similar to each other, can be subdivided
into two subgroups: Southeast Asia including Burma,
Nepal, and parts of India, and Northern and Central Asia,
including Pakistan, China, Kirgizia, and India (Tsarev et
al., 1992; Yin et al., 1994; Gouvea et al., 1997). Recently,
the genomes of several HEV strains from Africa were
partially sequenced (Chatterjee et al., 1997; van Cuyck-
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Gandre´ et al., 1997). Although quite distinct from all
known Asian strains, the African strains were more sim-
ilar to the Asian strains than to the Mexican strain. These
data suggest that the genetic heterogeneities of HEV
strains are geographically distributed and appear to fall
into four groups: Southeast Asian, Northern and Central
Asian, North American, and African (Yin et al., 1994;
Purcell, 1996; Chatterjee et al., 1997; van Cuyck-Gandre´
et al., 1997). More recently, an HEV strain isolated from
swine and another strain isolated from a patient with
acute hepatitis in the United States were grouped into a
new genotype of HEV (Meng et al., 1997b; Schlauder et
al., 1998).
Despite these observations in sequence heterogene-
ity, no significant serological differences were found be-
tween different HEV strains by immunoelectron micros-
copy and immunofluorescent assay (Bradley et al., 1988;
Bradley, 1990; Krawczynski et al., 1991). All diagnostic
tests based on recombinant HEV antigens (Yarbough et
al., 1991; Dawson et al., 1992; Goldsmith et al., 1992; Lok
et al., 1992; He et al., 1993; Tsarev et al., 1993), synthetic
peptides (Dawson et al., 1992; Khudyakov et al., 1993;
Favorov et al., 1994), or a mosaic HEV protein (Favorov et
al., 1996; Fields et al., 1996) can detect anti-HEV activity
in serum specimens from patients or primates experi-
mentally infected with HEV strains from different regions
of the world. Only the C-terminal region of the ORF3-
encoded protein demonstrated strain-specific antigenic
reactivity. A short fragment of the ORF3 protein derived
from the HEV Burma strain did not immunoreact with
serum samples from cynomolgus macaques (cynos) ex-
perimentally infected with the Mexico strain. Conversely,
a recombinant protein derived from the Mexico strain did
not immunoreact with serum specimens from cynos in-
fected with the Burma strain (Yarbough et al., 1991). This
strain specificity was also observed with several syn-
thetic peptides derived from the ORF3 protein (Khudya-
kov et al., 1993, 1994a; Coursaget et al., 1996).
In contrast, the heterogeneity of the HEV neutralization
immune response has not been thoroughly investigated.
Preliminary observations showed that cynos infected
with the Burma strain were immune to reinfection by the
Mexico strain (Bradley, 1990) and rhesus monkeys in-
fected with HEV from the former USSR were also immune
to subsequent challenge with an India strain (Arankalle
et al., 1993). In addition, the immunity elicited during
infection with one Indian HEV isolate protected against
different Indian HEV isolates (Arankalle et al., 1995).
These observations suggest that neutralizing anti-HEV
antibodies are protective against reinfection with either
the homologous or heterologous strains. However, only
one of two cynos immunized with a recombinant HEV
Burma strain ORF2 protein showed full protection
against challenge with the homologous Burma strain,
whereas another animal failed to protect against chal-
lenge with the Mexico strain. The animal challenged with
the Mexico strain resulted in HEV RNA in the stool and
HEV antigen in the liver, although no biochemical or
histological evidence of viral hepatitis was observed
(Purdy et al., 1993). Similarly, three of four cynos pas-
sively immunized with convalescent-phase plasma ob-
tained from a cyno infected with a pool of stool samples
containing two Chinese HEV isolates, although protected
against disease after challenge with the HEV Pakistan
strain SAR-55 with no histological evidence of infection,
were still infected, as demonstrated by both viremia and
fecal shedding of the virus. However, animals actively
immunized with a recombinant 55-kDa SAR-55 ORF2
protein developed neither hepatitis nor viremia when
challenged with the SAR-55 strain (Tsarev et al., 1994).
Likewise, Pillot et al. (1995) showed that infection with
one HEV strain may cause protection against disease
after challenge with either the homologous or heterolo-
gous strain isolated from Asia and Africa, but the protec-
tion was limited to preventing clinical disease and not
infection because the virus was found in the serum and
excreted in the stool. Collectively, these data suggest
that although anti-HEV activity contains neutralizing an-
tibody, the immunity elicited as the result of infection or
immunization may only protect against developing clini-
cal disease, and not infection. More experimental data
are needed before a final conclusion may be drawn
regarding the development of an effective HEV vaccine
that will protect against both disease and infection.
Cross-neutralization studies in experimentally infected
primates using many different HEV strains, although very
useful, may be cost prohibitive. Such an extensive study
may be best performed using in vitro approaches. Re-
cently, a new PCR-based HEV seroneutralization in vitro
assay was developed (Meng et al., 1997a). This assay
was shown to be highly specific and sufficiently sensitive
to detect cross-neutralization activity of antibodies
against different HEV strains. In this article, we used this
approach to study the neutralization of four different HEV
strains from Burma, Pakistan, Mexico, and Morocco, rep-
resenting the four groups of HEV as mentioned above,
with anti-HEV-positive serum samples obtained from dif-
ferent sources. The results of this study strongly suggest
broad cross-neutralization activity of antibodies elicited
during HEV infection. Conversely, immunization of labo-
ratory animals with several recombinant HEV proteins
elicited antibodies possessing only a limited range of
neutralization activity. Accordingly, recombinant proteins
should be carefully chosen as potential HEV vaccine
candidates.
RESULTS
PCR detection of HEV RNA of different geographic
HEV strains
Full-length nucleotide sequences of 11 different HEV
genomes available in GenBank were compared to iden-
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tify conserved regions suitable for designing universal
PCR primers. A conserved nucleotide region from posi-
tion 6347–6672 was identified as the most appropriate
for designing universal nested PCR primers. A set of four
PCR primers was synthesized (see Materials and Meth-
ods) and used to amplify with equal efficiency a specific
208-bp PCR fragment from stool specimens from either
cynos experimentally infected with the HEV Burma, Mex-
ico, or Pakistan strain or from patients infected with the
Morocco strain (data not shown).
Infection of PLC/PRF/5 cells with HEV Burma and
Mexico strains
As previously shown (Pillot et al., 1987; Meng et al.,
1996, 1997a), the cell line PLC/PRF/5 can be efficiently
infected with the HEV Pakistan SAR-55 and Morocco F23
strains. To demonstrate that this cell line is also suscep-
tible to infection with the HEV Burma and Mexico strains,
stool suspensions obtained from cynos experimentally
infected with the Burma strain or Mexico strain were
used to inoculate a monolayer of cells as described
previously (Meng et al., 1996). HEV RNA could be con-
tinuously detected in the supernatant or in the cells
during an incubation period of over 3 weeks (data not
shown). Thus, all four inocula used in this study were
shown to effectively infect PLC/PRF/5 cells.
Infectivity titration of HEV inocula
To identify end point infectivity titers, serial 10-fold
dilutions of each inoculum were prepared and inoculated
onto monolayers of PLC/PRF/5 cells. After incubation
and washing of the infected cells, RNA was extracted,
and HEV RNA was detected by reverse transcription
(RT)-PCR as previously described (Meng et al., 1996,
1997a). Infectivity titers for the Burma, Mexico, Pakistan,
and Morocco strains were 106, 108, 107, and 107 cell
culture infectious doses per gram of stool, respectively.
Titration experiments were repeated several times to
assess infectivity decay over time after storage of filtered
stool suspensions at 270°C. No loss of infectivity for any
of the four inocula was noted over an observation period
of .6 months (data not shown).
Titration of anti-HEV neutralizing activity
Preinoculation and convalescent-phase serum sam-
ples obtained from Cy9001, Cy9504, and G21A experi-
mentally infected with HEV Burma, Mexico, and Pakistan
strains, respectively, were diluted 2-fold from 1:5 with
Hanks’ balanced salt solution (HBSS). Approximately 100
cell culture infectious doses of the Burma inoculum were
mixed with each dilution of serum specimens collected
from the animal infected with the Burma strain. Similarly,
the Mexico or Pakistan inoculum was mixed with dilu-
tions of the homologous serum samples. Neutralizing
anti-HEV titers were determined by using the rapid PCR-
based seroneutralization assay. It was shown that con-
valescent-phase serum specimens collected 120 days
after infection of animals with the Burma or Mexico strain
neutralized the infectivity of the homologous Burma or
Mexico strains at 1:5, 1:10, and 1:20 dilutions, denoting a
neutralization titer of 1:20. For the Pakistan strain, serum
samples collected on the 54th day after infection neu-
tralized the infectivity at the 1:40 dilution. In each case,
preinoculation serum specimens did not neutralize the
homologous virus.
Cross-neutralization of HEV strains with cyno serum
Convalescent-phase serum samples obtained from
Cy9001, Cy9504, and G21A as described above were
diluted 1:20, 1:20, and 1:40, respectively. Preinoculation
serum specimens were diluted 1:10 as negative controls.
Each dilution was mixed with ;100 cell culture infectious
doses of the Burma, Mexico, Pakistan, and Morocco
strains. Neutralization activity was determined by the
rapid PCR-based seroneutralization assay. As shown in
Table 1, none of the preinoculation serum specimens
demonstrated any cross-neutralizing activity. In contrast,
all of the convalescent-phase serum samples collected
from the animals experimentally infected with the Burma,
Mexico, and Pakistan strains demonstrated cross-
neutralizing activity for each strain of HEV. Replicates of
this experiment are also indicated in Table 1. This exper-
iment confirms that cynos infected with any of the HEV
strains used in this study elicit antibodies possessing
broad cross-neutralization activity.
Cross-neutralization of HEV strains with human
serum obtained from HEV-endemic regions
Eight human convalescent-phase serum samples ob-
tained from individuals residing in Burma (one), India
TABLE 1
Cross-Neutralization of the HEV Burma, Mexico, Pakistan, and
Morocco Strains with Serum Samples Obtained from Cynomolgus
Macaques Experimentally Infected with the Burma, Mexico, and Pa-
kistan Strains
Serum sample
Cross-neutralization with HEV strains
Burma Mexico Pakistan Morocco
Cy9001 (Burma; preinoculant) 222a 222 22 2
Cy9001 (Burma; convalescent,
day 120) 111 211 11 11
Cy9504 (Mexico; preinoculant) 222 222 2 2
Cy9504 (Mexico;
convalescent, day 120) 2121 121 11 21
G21A (Pakistan; preinoculant) 2 2 2 2
G21A (Pakistan; convalescent,
day 54) 111 111 1 11
a Results of replicate assays.
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(two), China (one), Nepal (one), Somalia (two), and Mex-
ico (one) were diluted 1:10 with HBSS and mixed with
;100 cell culture infectious doses of either Burma, Mex-
ico, Pakistan, and Morocco strains of HEV. After incuba-
tion and inoculation of cell monolayers, the cross-neu-
tralization activity was determined by the rapid PCR-
based seroneutralization assay. The results of these
experiments (Table 2) confirm that HEV-infected individ-
uals residing in HEV-endemic regions of the world elicit
antibodies that cross-neutralize the infectivity of different
HEV strains.
Cross-neutralization of HEV strains with human
serum obtained from U.S. residents
Eight human convalescent-phase serum samples from
U.S. residents with a history of travel to HEV-endemic
regions including India, Nepal, Pakistan, Bangladesh,
Middle East, and Uruguay before the onset of hepatitis E
were diluted 1:10 with HBSS and mixed with the Burma,
Mexico, Pakistan, and Morocco strains of HEV, respec-
tively. Following the same experimental protocol that was
described above, each convalescent-phase serum cross-
neutralized all four HEV strains as shown in Table 3. The
results of this neutralization experiment also confirm that
HEV-infected individuals who acquired their infection
while traveling to an HEV-endemic region of the world
elicit antibodies that cross-neutralize the infectivity of
different HEV strains.
Cross-neutralization of antibodies against HEV
recombinant proteins
Purified IgG obtained by immunization of laboratory
animals with three HEV recombinant proteins was
used to assess cross-neutralization of different HEV
strains. One recombinant protein represented the full-
length HEV Burma ORF2-encoded protein expressed
in the baculovirus expression system (Mcatee et al.,
1996). A second recombinant protein, C2, contained a
fragment of the HEV Burma ORF2 protein correspond-
ing to amino acid (aa) position 225–660 (Purdy et al.,
1992). A third recombinant protein was an artificial
mosaic antigen composed of three regions: (1) 394–
470 aa, 562–580 aa, and 631–660 aa from the ORF2-
encoded protein of the HEV Burma strain, (2) 91–123
aa from the ORF3-encoded protein of the HEV Mexico
strain, and (3) 91–123 aa from the ORF3-encoded pro-
tein of the HEV Burma strain (Khudyakov et al., 1994b).
Anti-ORF2 was prepared in rabbits, anti-C2 in guinea
pigs, and anti-mosaic protein in rabbits and guinea
pigs. Serial 2-fold dilutions of each purified IgG prep-
aration were tested against each of the four HEV
strains by the seroneutralization assay. As shown in
Table 4, both preparations of IgG anti-mosaic protein
failed to neutralize any of the HEV strains, whereas the
anti-ORF2 antibody neutralized the infectivity of only
the Burma and Pakistan strains and only at the lowest
TABLE 2
Cross-Neutralization of the HEV Burma, Mexico, Pakistan, and
Morocco Strains with Human Anti-HEV Positive Serum Specimens
Obtained from Different Geographic Regions
Serum sample
(1:10)
Cross-neutralization with HEV strains
Burma Mexico Pakistan Morocco
Burma 1 1 1 1
India (1) 111a 121 11 21
India (2) 1 1 1 1
China 111 121 11 11
Nepal 1 21 1 1
Somalia (1) 1 1 1 1
Somalia (2) 1 1 1 1
Mexico 111 121 11 11
a Results of replicate assays.
TABLE 3
Cross-Neutralization of the HEV Burma, Mexico, Pakistan, and Morocco Strains with Anti-HEV Positive Serum
Specimens Obtained from U.S. Residents Who Had a Travel History before Onset of Disease
Serum sample
(1:10) Travel location
Cross-neutralization with HEV strains
Burma Mexico Pakistan Morocco
96-44 India 1 1 1 1
96-58 Asia 1 1 1 1
96-155a Pakistan, India, Nepal 1 1 1 1
96-156a Pakistan, India, Nepal 1 21b 1 1
96-157a Pakistan, India, Nepal 11 11 11 121
96-227 Uruguay 1 1 1 21
97-3 Bangladesh 1 1 1 1
97-36 Middle East 1 1 1 1
a Same patient, different dates of serum collection.
b Results of replicate assays.
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dilution tested. No neutralization activity was observed
against the Mexico and Morocco strains. However,
IgG anti-C2 demonstrated efficient neutralization of
not only the HEV Burma and Pakistan strains but also
the Mexico strain, despite having a lower IgG concen-
tration compared with the IgG anti-ORF2 preparation
(Materials and Methods). Surprisingly, the infectivity of
the HEV Morocco strain was not neutralized by any of
the IgG preparations at any of the tested dilutions.
Because a pool of fecal specimens collected from 15
different individuals from one Morocco HEV outbreak
(see Materials and Methods) was used, a possible
explanation for the absence of neutralization may be
the existence of one or more neutralization resistant
variants in the pool. To examine this possibility, an
HEV PCR fragment obtained from the Morocco inocu-
lum and from inoculated cells before and after neu-
tralization was sequenced and compared. This com-
parison demonstrated complete identity between each
fragment (data not shown). This finding suggests that
despite the fact that the Morocco inoculum was com-
posed of a pool of 15 fecal specimens, the HEV ad-
sorbed onto the surface of inoculated cells is predom-
inant in this inoculum and therefore is representative
of the epidemic HEV strain. In addition, the absence of
any nucleotide changes identified within these se-
quences suggests that the HEV population in the Mo-
rocco inoculum is homogeneous. Thus, in contrast to
the observation made for antibodies elicited during a
natural HEV infection, only limited cross-neutralization
activity was observed for antibodies elicited against
ORF2 recombinant protein.
DISCUSSION
The rapid PCR-based HEV seroneutralization assay
previously described (Meng et al., 1997a) was used in
the present study to demonstrate that this assay is a very
reliable and highly reproducible in vitro approach to
evaluate the neutralizing activity found in various anti-
HEV serum specimens and that the method represents a
very efficient and fast alternative to in vivo animal mod-
els. As shown previously (Pillot et al., 1987; Meng et al.,
1996, 1997a) and again in this study, PLC/PRF/5 cells are
susceptible to infection with four different HEV strains.
Although no cytopathic effect appeared, HEV RNA could
be detected in HEV-inoculated cells for .3 weeks de-
spite extensive cell washing and a change of media
every 2–3 days. The detection of HEV RNA confirms that
this system satisfies at least the first step of the infection
process, namely, adsorption onto the surface of PLC/
PRF/5 cells. As a result, this system allows for the de-
velopment of a rapid in vitro seroneutralization assay to
evaluate the neutralizing activity of anti-HEV positive
serum specimens by blocking the adsorption process
onto the cell surface. A very similar system was devel-
oped to study the neutralizing antibody response to the
hepatitis C virus, a virus that remains refractory to prop-
agation in cell culture (Shimizu et al., 1994, 1996; Zibert et
al., 1997). These assays are based on using cell surface
receptors to specifically capture the virus, followed by
RT-PCR to efficiently detect the genome of the captured
virus. Using this system, antibody neutralization activity
may be assessed by demonstrating the absence of de-
tectable virus genome in inoculated cells. In the absence
of a reliable permissive cell culture system, the assay
may be used as a rapid alternative to primate models to
evaluate various recombinant proteins as potential vac-
cine candidates.
The results presented in this study confirm that con-
valescent-phase antibodies elicited as the result of in-
fection with one HEV strain can efficiently block adsorp-
tion of several HEV strains onto the surface of PLC/PRF/5
cells. This observation suggests that convalescent-
phase antibody can cross-neutralize the infectivity of
multiple HEV strains. Specifically, serum samples ob-
tained from cynos experimentally infected with the HEV
Burma, Mexico, or Pakistan strain neutralized the infec-
tivity of four HEV strains from Burma, Mexico, Pakistan,
and Morocco. Moreover, serum samples obtained from
individuals residing in HEV-endemic regions of the world
including Burma, India, China, Nepal, Somalia, and Mex-
ico, or obtained from U.S. residents with a history of
travel to HEV-endemic regions (including India, Pakistan,
Nepal, Uruguay, Bangladesh, and Middle East) before
the onset of the disease also neutralized the infectivity of
all four strains in vitro. Although very reproducible, es-
pecially when homologous virus and antibodies are
used, the HEV seroneutralization in vitro assay, when
TABLE 4
Neutralizing Effect of Purified IgG Obtained From Animals Immu-
nized with the Full-Length HEV ORF2 Protein, Recombinant C2-Pro-
tein, and HEV Mosaic Protein
Dilution of purified IgG
Cross-neutralization with HEV
strains
Burma Mexico Pakistan Morocco
Anti-ORF2 (from rabbits, 5.5 mg/ml)
1:10 1 2 1 2
1:20 2 2 2 2
Anti-C2 (from guinea pigs, 3.4 mg/ml)
1:10 1 1 1 2
1:20 1 1 1 2
1:40 1 1 1 2
1:80 1 1 1 2
1:160 1 1 1 2
1:320 1 1 1 2
1:640 2 2 1 2
1:1280 2 2 2 2
Anti-mosaic protein
From rabbits, 4.2 mg/ml, 1:10 2 2 2 2
From guinea pigs, 2.4 mg/ml, 1:10 2 2 2 2
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applied to Mexico and Morocco strains and serum sam-
ples of Asian origin, resulted in several inconsistent
results in replicate assays (Tables 1, 2, and 3). Similar
inconsistencies were observed previously (Meng et al.,
1997a) in which convalescent-phase serum specimens
obtained from a cyno experimentally infected with an
Algerian HEV isolate neutralized the infectivity of the
Pakistan strain (SAR-55) failed to definitively neutralize
the Morocco F23 strain. These observations may be
explained, at least in part, by variability in the efficiency
of neutralization during the short incubation period, by
low-titer anti-HEV neutralizing antibodies, or by both.
Alternatively, some fine antigenic heterogeneity that may
play a role in the neutralization activity may exist as the
result of aa sequence heterogeneity between different
HEV strains, as exemplified by a 7% sequence hetero-
geneity between the ORF2-encoded proteins of the HEV
strains from Mexico and Asia (Yin et al., 1994). In addi-
tion, sequence heterogeneity between the ORF3-
encoded proteins of the HEV Burma and Mexico strains
was shown to influence the antigenic heterogeneity of
this protein (Yarbough et al., 1991; Khudyakov et al., 1993,
1994a). Nevertheless, no strong evidence exists suggest-
ing that sequence and antigenic variations have any
effect on the HEV neutralizing antigenic epitope or
epitopes. A thorough evaluation of the antigenic diversity
of the ORF2 protein from different HEV isolates should be
established before any final conclusions are drawn on
the possible diversity of the HEV neutralization epitope
or epitopes and the neutralizing activity of anti-HEV an-
tibodies specific to different HEV strains.
The results obtained in this study with antibodies
against various HEV recombinant antigens provide addi-
tional evidence of the possible heterogeneity of the neu-
tralizing antigenic epitope or epitopes. Antibodies against
the recombinant proteins of the HEV Burma strain effec-
tively neutralized the HEV strains from Burma and Paki-
stan but showed no neutralizing activity against the HEV
Morocco strain. It should be noted, however, that the
HEV neutralizing antigenic epitope or epitopes may be
modeled with recombinant proteins differently from the
native epitope or epitopes. In addition, it is conceivable
that different recombinant proteins can model antigenic
epitopes with different efficiencies. In agreement with
this assumption, we found that antibodies against the
recombinant protein C2, which contains only a part of the
ORF2-encoded protein (Purdy et al., 1992), could neutral-
ize the infectivity of the HEV Mexico strain, whereas
antibodies against the full-length ORF2-encoded protein
(Mcatee et al., 1996) failed to neutralize the infectivity of
the same strain. Thus, antibodies to a shorter fragment of
the HEV ORF2 protein were shown to have more efficient
neutralizing activity than the full-length protein. The dif-
ference between the antigenic properties of a fragment
and the full-length HEV ORF2-encoded protein was re-
cently observed for the detection of convalescent-phase
anti-HEV using different HEV recombinant proteins (Li et
al., 1994, 1997). These experiments revealed that full-
length ORF2 protein was poorly reactive with convales-
cent-phase serum samples, whereas the C-terminal por-
tion of the ORF2 protein was highly reactive.
In conclusion, the data presented in this study suggest
that antibodies elicited during an HEV infection display
broad HEV-neutralizing activity, whereas antibodies elic-
ited after immunization with recombinant Burma ORF2
proteins demonstrate a more restricted ability to neutral-
ize various HEV strains obtained from different HEV-
endemic region of the world.
MATERIALS AND METHODS
Cell culture
PLC/PRF/5, a human hepatocarcinoma cell line, was
grown in Dulbecco’s modified Eagle’s medium (GIBCO
BRL, Grand Island, NY) supplemented with 10% heat-
inactivated fetal bovine serum (HyClone Laboratory, Lo-
gan, UT), and incubated at 37°C with 5% CO2. For virus
titration and for the neutralization assay, trypsinized cells
were seeded onto 24-well, flat-bottom culture plates at a
concentration of 105 cells per well.
Virus stocks
The HEV Burma strain was obtained from a fecal spec-
imen collected 17 days after experimental infection of a
cyno (Cy9210) inoculated with a stool pool from a third-
passage Burma strain-infected cyno (Cy73) (Bradley et al.,
1987). The HEV Mexico strain was from a fecal specimen
collected 21 days after experimental infection of a cyno
(Cy9218) inoculated with a stool suspension from a patient
(Mex 14) with hepatitis E during an outbreak in Telixtac,
Mexico. Mex 14 was shown previously to cause hepatitis E
in all experimentally infected cynos and chimpanzees
(Bradley et al., 1988; Bradley, 1990). Both Burma and Mexico
strains were kindly provided by K. McCaustland [Hepatitis
Branch, Centers for Disease Control and Prevention (CDC),
Atlanta, GA]. The HEV Pakistan strain, SAR-55 (Tsarev et al.,
1992), a gift provided by Dr. R. H. Purcell (Hepatitis Viruses
Section, National Institutes of Health, Bethesda, MD), was
obtained from a fecal specimen of an experimentally in-
fected rhesus monkey 21 days after intravenous inoculation
(Pillot et al., 1995). The HEV Morocco strain was obtained
from a fecal pool of 15 patients with well-documented
epidemic hepatitis E who were residing in the area of
Casablanca, Morocco (Benjelloun et al., 1997). Each fecal
specimen was prepared as a 10% (wt/vol) suspension in
PBS, filtered through a Sterilization Filter Unit (Nalge Com-
pany, Rochester, NY), and stored at 270°C.
Serum samples
Burma anti-HEV serum was collected from a cyno
(Cy9001) 120 days after inoculation with the HEV
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Burma inoculum obtained from Cy73. Mexico anti-HEV
serum was collected from a cyno (Cy9504) 120 days
after inoculation with the HEV Mex 14 inoculum. These
two serum specimens were kindly provided by J. Spel-
bring (Hepatitis Branch, CDC). Pakistan anti-HEV se-
rum was collected from a cyno (G21A) 54 days after
inoculation with SAR-55. Preinoculation serum sam-
ples were obtained from each animal before experi-
mental infection. Eight human serum specimens (kind-
ly provided by Dr. M. Favorov and K. McCaustland,
Hepatitis Branch, CDC) were obtained from con-
valescent patients from different geographic regions
(Burma, India, China, Nepal, Somalia, and Mexico).
Another eight convalescent-phase human serum
specimens (kindly provided by S. Lambert and Dr. E.
Mast, Hepatitis Branch, CDC) were obtained from in-
dividuals residing in the United States. All eight indi-
viduals reported a travel history to India, Nepal, Paki-
stan, Bangladesh, Middle East, or Uruguay and re-
turned to the United States within the expected
incubation period before the onset of disease. All of
the preinoculation and convalescent-phase serum
samples were inactivated at 56°C for 30 min. Only the
convalescent-phase serum specimens were shown to
contain anti-HEV activity by enzyme immunoassay us-
ing both an HEV mosaic antigen (Khudyakov et al.,
1994b) and a commercially available kit (Genelabs
Diagnostics, Singapore).
Purified IgG
Anti-ORF2 IgG, at a concentration of 5.5 mg/ml, was
prepared from serum specimens of rabbits immunized
with a full-length Burma strain ORF2-encoded, 73-kDa
protein expressed in insect cells using a recombinant
baculovirus (Mcatee et al., 1996). Anti-C2 IgG, at a
concentration of 3.4 mg/ml, was prepared from serum
samples of guinea pigs immunized with a trpE-HEV
fusion protein (C2 protein) that represents the carboxyl
two thirds of the putative capsid protein of the Burma
strain and expressed in Escherichia coli with a pATH
expression system (Purdy et al., 1992). Both IgG anti-
ORF2 and anti-C2 were kindly provided by Dr. M. Purdy
(Hepatitis Branch, CDC). IgG anti-mosaic protein, at a
concentration of 4.2 mg/ml, was prepared from serum
samples of rabbits immunized with an HEV-specific
artificial mosaic protein consisting of a series of short
(10–22 aa) linear antigenic epitopes from ORF2 and
ORF3 of both the Burma and Mexico strains and ex-
pressed in E. coli as a chimera with glutathione-S-
transferase (Khudyakov et al., 1994b). Another IgG
anti-mosaic protein, at a concentration of 2.4 mg/ml,
was prepared from serum specimens of guinea pigs
immunized with the same HEV mosaic protein. Both
IgG anti-mosaic proteins were kindly provided by Dr.
M. Favorov (Hepatitis Branch, CDC).
Rapid PCR-based seroneutralization assay in cell
culture
This protocol has been previously described (Meng et
al., 1997a), except for the PCR primers used in this study.
Briefly, ;100 cell culture infectious doses of an HEV
inoculum diluted in 100 ml of HBSS were mixed with 100
ml of a serum sample at an appropriate dilution. After
incubation at 37°C for 1 h, the mixture was inoculated
onto a cell monolayer of PLC/PRF/5. After adsorption for
2 h at 37°C, the cells were washed three times with
HBSS followed by immediate RNA extraction with TRIzol
reagent (GIBCO BRL) according to the manufacturer’s
instructions. RT-nested PCR was performed by using a
set of universal HEV PCR primers. The outer primers
were YK-1291 (59-GTT GTC TCA GCC AAT GGC GAG CC)
and YK-1294 (59-GCC TGC GCG CCG GTC GCA ACA),
and the inner primers were YK-1292 (59-TGG AGA ATG
CTC AGC AGG ATA A) and YK-1293 (59-TAA GTG GAC
TGG TCG TAC TCG GC). Both the first- and second-round
amplifications were carried out according to the follow-
ing cycling program: denaturation at 94°C for 45 s, an-
nealing at 60°C for 20 s, and extension at 72°C for 60 s
and for 30 cycles. Amplicons were separated by agarose
gel electrophoresis with size markers and visualized by
ethidium bromide fluorescence. Neutralization was de-
termined by the absence of detectable HEV RNA in the
inoculated cell culture. A negative serum control, virus
control, and uninoculated cell control were always pro-
cessed for the detection of HEV RNA at the same time for
each assay.
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